Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00425347
• Other study ID #: HuLuc63-1701
• Status: Completed
• Phase: Phase 1
• First received: January 18, 2007
• Last updated: September 21, 2009
• Start date: December 2006
• Est. completion date: July 2009

Study information

• Verified date: September 2009
• Source: Facet Biotech
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To identify the MTD of HuLuc63 administered intravenously (IV) for 4 doses.2. To evaluate the safety of HuLuc63 IV given every other week for 4 doses.

Other known NCT identifiers

• NCT00429741

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: July 2009
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:

• Males or females, age 18 years or older.

• Diagnosis of advanced multiple myeloma, after at least 2 prior therapies for MM.

• Measurable disease M component in serum (at least 0.5 G/dL) and/or urine (=0.2 g excreted in a 24-hour collection sample).

• Not eligible for stem cell or bone marrow transplant or have refused stem cell or bone marrow transplant or have relapsed after autologous or allogeneic stem cell or bone marrow transplant.

• ECOG performance status 0-2 (Appendix E).

• ALT or AST =3 x ULN.

• Total bilirubin =2 x ULN (unless related to MM).

• Serum creatinine =2.0 mg/dL (unless related to MM, then = 3.0 mg/dL).

• Must have adequate bone marrow function defined as: Absolute neutrophil count >1,000 cells/mm3; platelets =75,000 cells/mm3; and hemoglobin =8 g/dL. No platelet transfusion within 72 hours of obtaining screening platelet count.

• Serum calcium (corrected for albumin) level within normal range (treatment of hypercalcemia is allowed and subject may enroll if hypercalcemia returns to normal with treatment).

• Signed and dated informed consent.

• Use of appropriate contraception where applicable.

• Negative pregnancy test within 48 hours prior to first dose in women of childbearing potential.

• Must have 2-dimensional echocardiogram or MUGA indicating LVEF = 45% within 30 days prior to first dose of study drug.

• Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations).

Exclusion Criteria:

Subjects will be ineligible for this study if they meet any one of the following criteria:

• Life expectancy of less than 3 months.

• Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for at least 5 years.

• Plasma cell leukemia (active or prior).

• Uncontrolled medical problems such as diabetes mellitus, coronary artery disease, hypertension, unstable angina, arrhythmias, pulmonary, hepatic, and renal diseases unless renal insufficiency is felt to be secondary to multiple myeloma (serum creatinine > 2.0 mg/dL).

• Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia.

• Corticosteroid, Velcade® or other proteosome inhibitor, thalidomide, lenalidomide (Revlimid®), or melphalan within 2 weeks of the first dose of HuLuc63; nitrogen mustard agents within 6 weeks of the first dose of HuLuc63.

• Investigational drug within 4 weeks or 5 half-lives (whichever is greater) of the first dose of HuLuc63.

• Stem cell or bone marrow transplant within 12 weeks prior to the first dose of HuLuc63.

• Biological agents including intravenous immune globulin (IVIG) and monoclonal antibodies within 4 weeks of the first dose of HuLuc63.

• Neuropathy >Grade 2 (according to the NCI CTCAE v3.0 criteria scale).

• Symptomatic orthostatic hypotension.

• Evidence of amyloidosis.

• Known active infections requiring antibiotics, antivirals, or antifungals.

• Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation.

• Hypersensitivity to recombinant proteins or excipients in the investigational agent.

• Any condition that in the investigator's opinion makes the subject unsuitable for study participation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• HuLuc63
Not applicable for HuLuc63.

Locations

Country	Name	City	State
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Northwestern University Feinberg School of Medicine	Chicago	Illinois
United States	Cleveland Clinic	Cleveland	Ohio
United States	Wayne State University	Detroit	Michigan
United States	Arkansas Cancer Research Center	Little Rock	Arkansas
United States	USC/Norris Cancer Hospital	Los Angeles	California
United States	Fred Hutchinson Cancer Research Center	Seattle	Washington
United States	University of Massachusetts Memorial Healthcare- Univ. Campus	Worcester	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Facet Biotech

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Not applicable for this trial.		Not applicable for this trial.	No

External Links

•   Link